|
1
|
Gandaglia G, Popa I, Abdollah F,
Schiffmann J, Shariat SF, Briganti A, Montorsi F, Trinh QD,
Karakiewicz PI and Sun M: The effect of neoadjuvant chemotherapy on
perioperative outcomes in patients who have bladder cancer treated
with radical cystectomy: A population-based study. Eur Urol.
66:561–568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu HJ, Chang YH and Pan CC: Prognostic
significance of heat shock proteins in urothelial carcinoma of the
urinary bladder. Histopathology. 62:788–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S,
Li J, Wu F, Zhang H, Zhao Z, et al: A potent chemotherapeutic
strategy with Eg5 inhibitor against gemcitabine resistant bladder
cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang HW, Yoon HY, Ha YS, Kim WT, Kim YJ,
Yun SJ, Lee SC and Kim WJ: FAM70B as a novel prognostic marker for
cancer progression and cancer-specific death in muscle-invasive
bladder cancer. Korean J Urol. 53:598–606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Allory Y, Beukers W, Sagrera A, Flández M,
Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I,
Vermeij M, et al: Telomerase reverse transcriptase promoter
mutations in bladder cancer: High frequency across stages,
detection in urine, and lack of association with outcome. Eur Urol.
65:360–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenberg JE: Current status of
neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder
cancer. Expert Rev Anticancer Ther. 7:1729–1736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hodge LS, Taub ME and Tracy TS: Effect of
its deaminated metabolite, 2,2-difluorodeoxyuridine, on the
transport and toxicity of gemcitabine in HeLa cells. Biochem
Pharmacol. 81:950–956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leijen S, Veltkamp SA, Huitema AD, van
Werkhoven E, Beijnen JH and Schellens JH: Phase I dose-escalation
study and population pharmacokinetic analysis of fixed dose rate
gemcitabine plus carboplatin as second-line therapy in patients
with ovarian cancer. Gynecol Oncol. 130:511–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hua S, Wang Z, Jiang K, Huang Y, Ward T,
Zhao L, Dou Z and Yao X: CENP-U cooperates with Hec1 to orchestrate
kinetochore-microtubule attachment. J Biol Chem. 286:1627–1638.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minoshima Y, Hori T, Okada M, Kimura H,
Haraguchi T, Hiraoka Y, Bao YC, Kawashima T, Kitamura T and
Fukagawa T: The constitutive centromere component CENP-50 is
required for recovery from spindle damage. Mol Cell Biol.
25:10315–10328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanissian SH, Akbar U, Teng B, Janjetovic
Z, Hoffmann A, Hitzler JK, Iscove N, Hamre K, Du X, Tong Y, et al:
cDNA cloning and characterization of a novel gene encoding the
MLF1-interacting protein MLF1IP. Oncogene. 23:3700–3707. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanissian SH, Teng B, Akbar U, Janjetovic
Z, Zhou Q, Duntsch C and Robertson JH: Regulation of myeloid
leukemia factor-1 interacting protein (MLF1IP) expression in
glioblastoma. Brain Res. 1047:56–64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai W and Wang X: Grabbing Plk1 by the
PBD. Mol Cell. 24:489–490. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee KS, Oh DY, Kang YH and Park JE:
Self-regulated mechanism of Plk1 localization to kinetochores:
Lessons from the Plk1-PBIP1 interaction. Cell Div. 3:42008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hori T, Okada M, Maenaka K and Fukagawa T:
CENP-O class proteins form a stable complex and are required for
proper kinetochore function. Mol Biol Cell. 19:843–854. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Foltz DR, Jansen LE, Black BE, Bailey AO,
Yates JR III and Cleveland DW: The human CENP-A centromeric
nucleosome-associated complex. Nat Cell Biol. 8:458–469. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang DP and Luo RC: MLF1IP is correlated
with progression and prognosis in luminal breast cancer. Biochem
Biophys Res Commun. 477:923–926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Ji G, Shao Y, Qiao S, Jing Y, Qin
R, Sun H and Shao C: MLF1 interacting protein: A potential gene
therapy target for human prostate cancer? Med Oncol.
32:4542015.PubMed/NCBI
|
|
19
|
Radhika K and Prayaga AK: Estrogen and
progesterone hormone receptor status in breast carcinoma:
Comparison of immunocytochemistry and immunohistochemistry. Indian
J Cancer. 47:148–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vasconcelos-Nóbrega C, Pinto-Leite R,
Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira
C, Salvador A, Guedes-Teixeira CI, Colaço A, et al: In vivo and in
vitro effects of RAD001 on bladder cancer. Urol Oncol.
31:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gazzaniga P, Silvestri I, Gradilone A,
Scarpa S, Morrone S, Gandini O, Gianni W, Frati L and Aglianò AM:
Gemcitabine-induced apoptosis in 5637 cell line: An in-vitro model
for high-risk superficial bladder cancer. Anticancer Drugs.
18:179–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee YG, Macoska JA, Korenchuk S and Pienta
KJ: MIM, a potential metastasis suppressor gene in bladder cancer.
Neoplasia. 4:291–294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki H, Arakawa Y, Ito M, Saito S,
Takeda N, Yamada H and Horiguchi-Yamada J: MLF1-interacting protein
is mainly localized in nucleolus through N-terminal bipartite
nuclear localization signal. Anticancer Res. 27:1423–1430.
2007.PubMed/NCBI
|
|
26
|
Dominguez-Valentin M, Therkildsen C,
Veerla S, Jönsson M, Bernstein I, Borg A and Nilbert M: Distinct
gene expression signatures in lynch syndrome and familial
colorectal cancer type x. PLoS One. 8:e717552013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang W, Jiang H, Zhu H, Zhang H, Gong J,
Zhang L and Ding Q: Overexpression of high mobility group box 1 and
2 is associated with the progression and angiogenesis of human
bladder carcinoma. Oncol Lett. 5:884–888. 2013.PubMed/NCBI
|
|
28
|
Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG,
Cao M, Liu DM and Huang YR: Increased expression of HMGB1 is
associated with poor prognosis in human bladder cancer. J Surg
Oncol. 106:57–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang Z, Zhong Z, Zhang L, Wang X, Xu R,
Zhu L, Wang Z, Hu S and Zhao X: Down-regulation of HMGB1 expression
by shRNA constructs inhibits the bioactivity of urothelial
carcinoma cell lines via the NF-κB pathway. Sci Rep. 5:128072015.
View Article : Google Scholar : PubMed/NCBI
|
